Synairgen plc
('Synairgen' or the 'Company')
Martin Murphy appointed as Non-Executive
Director
Southampton, UK - 16 January
2025: Synairgen plc (LSE: SNG), the respiratory company developing
SNG001, an investigational formulation for inhalation containing
the broad-spectrum antiviral protein interferon beta, today
announces the appointment of Martin Murphy to the Board as an
independent Non-Executive Director and Chair of the Remuneration
Committee, effective immediately.
Martin Murphy is a seasoned
healthcare veteran with over 25 years of leadership experience in
life sciences investment. Previously, Martin Murphy was co-founder
of Syncona Limited, a FTSE 250 healthcare investment company, and
CEO and Investment Committee Chair of Syncona Investment Management
Limited. He now holds various Chair positions and is a Director and
founding investor of NASDAQ-listed Autolus Therapeutics plc.
Between 2005-2012, he served as a Managing Director of MVM Life
Science Partners LLP. Martin holds a PhD from the University of
Cambridge and an MA in Biochemistry from the University of
Oxford.
Mark Parry-Billings, Chairman of the Board of Synairgen,
added: "I'm pleased to welcome Martin Murphy to our Board at
Synairgen, where his proven track record in guiding innovative
healthcare companies will strengthen our strategic direction.
Martin's extensive experience in life sciences leadership will
prove invaluable as we prepare to begin our large Phase 2 INVENT
trial in the coming months."
Martin Murphy, Non-Executive Director of the Board of
Synairgen, commented: "I am delighted to be
joining Synairgen's Board at this pivotal stage as the Company
plans to progress its INVENT trial investigating SNG001 in
mechanically ventilated patients. I look forward to collaborating
with the team and supporting the advancement of this potentially
transformative treatment for a patient group in critical
need."
The following information regarding
the appointment of Martin Murphy, aged 56, is disclosed under
Schedule 2(g) of the AIM Rules for Companies:
|
Full name:
|
Martin Patrick Murphy
|
|
Age:
|
56
|
|
Shares held in the
Company:
|
None
|
|
Current directorships and/or
partnerships:
|
Former directorships and/or
partnerships (within the last five years):
|
|
Autolus Therapeutics PLC (formerly
Autolus Therapeutics Limited)
|
Achilles Therapeutics UK
Limited
|
|
|
Anaveon AG
|
|
|
Azeria Therapeutics
Limited
|
|
|
Clade Therapeutics, Inc.
|
|
|
Neogene Therapeutics,
Inc.
|
|
|
Quell Therapeutics
Limited
|
|
|
Resolution Therapeutics
Limited
|
|
|
Syncona Development
Limited
|
|
|
Syncona Discovery Limited
|
|
|
Syncona Investment Management
Limited
|
|
|
Syncona IP Holdco (2)
Limited
|
|
|
Syncona IP Holdco Limited
|
There are no further disclosures to
be made under Schedule 2(g) of the AIM Rules for
Companies.
For
further enquiries, please contact:
|
Synairgen plc
|
+ 44 (0)23 8051 2800
|
|
Media@synairgen.com
|
|
|
Cavendish Capital Markets Limited -
Nominated Adviser, joint broker and sole
bookrunner
|
+ 44 (0)20 7220 0500
|
|
Geoff Nash/Camilla Hume/Trisyia
Jamaludin
Deutsche Numis (Joint Broker)
Freddie Barnfield, Duncan Monteith,
Euan Brown
|
+ 44 (0) 20 7260 1000
|
|
ICR
Healthcare (Financial Media and Investor
Relations)
|
+ 44 (0)20 3709 5700
|
|
Mary-Jane Elliott/Namrata Taak/Lucy
Featherstone
synairgen@icrhealthcare.com
|
|
Notes for
Editors
About Synairgen
Synairgen is a UK-based respiratory
company focused on drug discovery and the development of SNG001
(inhaled interferon beta) as potentially the first host-targeted,
broad-spectrum antiviral treatment delivered directly into the
lungs for severe viral lung infections.
Millions of people globally are
hospitalised every year due to viral lung infections and there are
currently no approved antiviral therapies for the majority of these
patients. Synairgen is developing SNG001 to address this
need.
Synairgen is quoted on AIM (LSE:
SNG). For more information about Synairgen, please see
www.synairgen.com